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Abstract
Introduction: By 2020, 90% of all people diagnosed with HIV should receive long-term combination antiretroviral therapy
(ART). In sub-Saharan Africa, this target is threatened by loss to follow-up in ART programmes. The proportion of people
retained on ART long-term cannot be easily determined, because individuals classified as lost to follow-up, may have self-
transferred to another HIV treatment programme, or may have died. We describe retention on ART in sub-Saharan Africa,
first based on observed data as recorded in the clinic databases, and second adjusted for undocumented deaths and self-
transfers.
Methods: We analysed data from HIV-infected adults and children initiating ART between 2009 and 2014 at a sub-Saharan Afri-
can HIV treatment programme participating in the International epidemiology Databases to Evaluate AIDS (IeDEA). We used the
Kaplan–Meier method to calculate the cumulative incidence of retention on ART and the Aalen–Johansen method to calculate
the cumulative incidences of death, loss to follow-up, and stopping ART. We used inverse probability weighting to adjust clinic
data for undocumented mortality and self-transfer, based on estimates from a recent systematic review and meta-analysis.
Results: We included 505,634 patients: 12,848 (2.5%) from Central Africa, 109,233 (21.6%) from East Africa, 347,343
(68.7%) from Southern Africa and 36,210 (7.2%) from West Africa. In crude analyses of observed clinic data, 52.1% of patients
were retained on ART, 41.8% were lost to follow-up and 6.0% had died 5 years after ART initiation. After accounting for
undocumented deaths and self-transfers, we estimated that 66.6% of patients were retained on ART, 18.8% had stopped ART
and 14.7% had died at 5 years.
Conclusions: Improving long-term retention on ART will be crucial to attaining the 90% on ART target. Na€ıve analyses of HIV
cohort studies, which do not account for undocumented mortality and self-transfer of patients, may severely underestimate
both mortality and retention on ART.
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1 | INTRODUCTION
Over the past 15 years antiretroviral therapy (ART) has been
scaled up massively in low- and middle-income countries: by
mid-2017 globally almost 21 million people were receiving
ART [1]. According to modelling by the Joint United Nations
Programme on HIV/AIDS (UNAIDS), 1.2 million deaths have
been averted due to ART and 35% of the worldwide new HIV
infections prevented by ART [1]. In 2014, UNAIDS launched
the “90-90-90” targets and “treatment as prevention” became
a priority of the global response to the HIV epidemic [2–6]:
by 2020, 90% of all people living with HIV know their status,
90% of those diagnosed receive ART, and 90% of the people
on ART have undetectable viral load. The 90-90-90 strategy
aims to ensure that the majority of people living with HIV are
on successful ART and no longer transmit the virus, thus end-
ing the AIDS epidemic as a public health threat by 2030.
In line with the 90-90-90 strategy, the latest HIV treatment
guidelines recommend that all people living with HIV should
initiate ART regardless of clinical stage and CD4 cell count. A
key barrier to ART uptake, the requirement to undergo CD4
testing prior to ART initiation, was thus removed [4,7], facili-
tating early initiation of ART. However, persons successfully
initiated on ART need to continue ART for life. Patients who
stop taking ART rapidly lose the benefits of viral suppression
and may transmit the virus or fall sick [8]. Retaining people on
ART is a challenge in sub-Saharan Africa. A recent systematic
review of cohort studies from sub-Saharan Africa showed that
every third ART patient was classified as lost to follow-up
within 3 years of starting ART [9]. The proportion of patients
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who stopped taking ART cannot be easily determined from
clinic data, because patients classified as lost to follow-up may
have self-transferred to another HIV treatment programme,
or may have died [10–12].
The true status of persons lost to follow-up can be deter-
mined through tracing by phone calls and home visits. A
recent meta-analysis of tracing studies from African HIV pro-
grammes showed that about one-third of all patients lost to
follow-up had self-transferred to another ART facility, one-
third had stopped taking ART, and one-third had died [11].
Tracing outcomes can be used to adjust estimates for
mortality and treatment discontinuation from cohort studies
[13–16].
We first describe mortality, loss to follow-up and retention
on ART among HIV-infected children and adults who initiated
ART in sub-Saharan Africa, as recorded by the HIV care pro-
grammes. We then adjust analyses for undocumented mortal-
ity and self-transfer to estimate the proportion of patients
who died, stopped ART, and are retained on ART in Central,
East, West and Southern Africa.
2 | METHODS
2.1 | Data sources
The International epidemiology Databases to Evaluate AIDS
(IeDEA) is a global consortium of HIV cohort studies. We
included all HIV treatment cohorts that participate in IeDEA
Central Africa, East Africa, Southern Africa, and West Africa
[17]. Fifty-seven cohorts from 22 countries contributed data,
including 3 cohorts from Burundi, 2 from the Democratic
Republic of the Congo, 10 from Rwanda (Central African
region); 2 cohorts from Kenya, 1 from Tanzania, 4 from
Uganda (East Africa); 1 cohort from Lesotho, 2 from Malawi,
1 from Mozambique, 7 from South Africa, 1 from Zambia and
2 from Zimbabwe (Southern Africa); 1 cohort from Benin, 2
from Burkina Faso, 8 from Co^te d’Ivoire, 1 from Ghana, 1
from Guinea, 1 from Guinea-Bissau, 2 from Mali, 2 from Nige-
ria, 2 from Senegal and 1 from Togo (West Africa). In Central
Africa and West Africa most participating sites were urban
regional, provincial, or university hospitals. In East and South-
ern Africa they were health centres, district hospitals and
regional, provincial, and university hospital from urban and
rural settings. The number of patients ranged from 42
patients in the Nyarugunga clinic in Rwanda, to almost
230,000 patients at the Centre for Infectious Disease
Research in Zambia (CIDRZ). Data are collected during rou-
tine care at ART initiation and at each follow-up visit, includ-
ing socio-demographic information, date of ART start, type of
ART, and (where available) CD4 counts and viral load mea-
surements. Regional IeDEA data centres sent de-identified
data to the University of Bern, Switzerland for cleaning and
analysis.
2.2 | Eligibility criteria
We included HIV-infected adults and children who initiated
ART during 2009 to 2014 at one of the HIV treatment pro-
grammes that participate in IeDEA Central Africa, East Africa,
Southern Africa and West Africa. We excluded patients known
not to be ART-na€ıve at enrolment. Individuals who received
antiretroviral drugs to prevent mother-to-child transmission or
for pre- or post-exposure prophylaxis prior to starting ART
were considered ART experienced and excluded.
2.3 | Outcomes
For the analyses of the data as recorded in the clinical data-
bases, outcomes were retention on ART, loss to follow-up, and
death. Outcomes were mutually exclusive. For the definition of
loss to follow-up, we calculated a patient’s next appointment
date as the last visit date plus a patient’s most recent gap
between two consecutive visits that was in accordance with
the visit schedule of the clinic. We then classified patients
more than 90 days late for their next clinic appointment who
did not return to care during the study period as lost to fol-
low-up on the day of the first missed appointment. In the
adjusted analyses, outcomes were retention on ART, death,
and stopping ART. We assumed that patients recorded as lost
to follow-up by a treatment programme who were not classi-
fied as self-transfer or unrecorded death were alive and had
stopped ART.
2.4 | Statistical analyses
We used descriptive statistics to describe patient’s character-
istics at initiation of ART, stratified by IeDEA region. We
used survival analysis methods to analyse time to loss to fol-
low-up, stopping ART and death. We followed patients from
ART initiation for a maximum of 5 years, censoring follow-up
time of patients who transferred to another clinic or pro-
gramme that was not covered by IeDEA on the date of
transfer. Individuals retained on ART were censored 90 days
before database closure, when they ceased to be at risk of
loss to follow-up. We used the Kaplan–Meier estimator to
calculate the cumulative probability of retention on ART and
the Aalen-Johansen estimator to calculate the cumulative
incidences of documented death or loss to follow-up and
stopping ART. Death and loss to follow-up or stopping ART
were competing risks [18].
In a second, adjusted analysis, we adjusted estimates to
account for undocumented mortality and self-transfer of
patients to another HIV treatment programme using inverse
probability weighting. Weights were based on the results from
a recent meta-analysis of 32 studies of 20,365 patients who
were lost to follow-up on ART in sub-Saharan Africa [11]. In
these studies, patients were traced by phone calls or home
visits. In South Africa, their vital status was assessed through
the vital registration system [11]. This meta-analysis showed
that mortality in patients lost to follow-up declined in recent
years, whereas undocumented transfers to other clinics
increased [11]. Based on these data, we assumed that 20.8%
of all patients recorded as loss to follow-up had died, and
35.9% had self-transferred to another facility. These estimates
correspond to the meta-analysis’ estimates for the year 2012,
which was the mid-study year of our analysis. Patients classi-
fied as loss to follow-up were down weighted by 1 minus the
probability that they had been misclassified due to underre-
porting of death or transfer. Patients classified as dead or
retained in care were up weighted by the inverse probability
of observing death or retention, given underreporting of death
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and transfer. The formulas used to calculate the weights are
given in Box 1. In a sensitivity analysis, we calculated weights
based on the upper and lower limits of the 95% confidence
intervals (CIs) around the estimates for mortality (11.3 to
35.1%) and self-transfer (16.8 to 60.9%) among patients lost
to follow-up [11].
Box 1. Calculation of weights to adjust for undocumented
mortality and undocumented transfer
We calculated the weights using the following formulas:
WLTF = 1  pdead  ptransfer, for patients lost to follow-up
(LTF)
Wdead ¼ 1ndead
ndeadþpdeadnLTF
; for patients who died
WRIC ¼ 1nRIC
nRICþptransfernLTF
; for patients retained in care ðRICÞ
where
ndead = number of patients known to be dead
nLTF = number of patients lost to follow-up (LTF)
nRIC = number of patients retained in care
pdead = proportion of patients LTF who were found to
have died (derived from [11])
ptransfer = proportion of patients LTF who silently trans-
ferred (derived from [[11])
2.5 | Ethical considerations
Local review boards and ethics committees approved the use
of the data included in this study. The Cantonal Ethics Com-
mittee of the Canton of Bern, Switzerland, approved data
merging and the collaborative analyses. Local review boards
and the Cantonal Ethics Committee of the Canton of Bern
waived the requirement to obtain informed consent.
3 | RESULTS AND DISCUSSION
We included 505,634 patients: 12,848 (2.5%) from Central
Africa, 109,233 (21.6%) from East Africa, 347,343 (68.7%)
from Southern Africa and 36,210 (7.2%) from West Africa.
The median (interquartile range, IQR) age at ART initiation
was 33.7 years (27.1 to 41.0); 22,939 (4.5%) patients were
under 5 years, 21,115 (4.2%) were aged 5 to 14 years and
461,580 (91.3%) were 15 years or older. The majority
(318,491; 63.0%) were female. Median CD4 cell count (IQR)
at ART initiation was 200 cells/lL (102 to 311 cells/lL).
Patient characteristics are shown in Table 1.
Figure 1 shows cumulative retention, loss to follow-up, and
mortality based on the data recorded in the clinics’ databases
(panel A), and cumulative retention, stopping ART, and mortal-
ity from the adjusted analysis that take unobserved deaths and
transfers among patients lost to follow-up into account (panel
B). As expected, retention and mortality were higher in the
adjusted analysis. Overall, cumulative retention declined from
76.8% (95% CI 76.7 to 77.0) at year 1 to 52.1% (51.9 to 52.3)
at year 5 in the crude analysis, and from 83.1% (83.0 to 83.2)
to 66.6% (66.4 to 68.8) in the adjusted analysis. Cumulative
mortality increased from 3.5% (3.5 to 3.6) in year 1 to 6.0%
(6.0 to 6.1) in year 5 in the crude analysis and from 8.4% (8.3
to 8.4) to 14.7% (14.5 to 14.8) in the adjusted analysis. In the
adjusted analysis, the percentage of patients who stopped ART
increased from 8.5% (8.5 to 8.6) at year 1 to 18.8% (18.6 to
18.9) at year 5. In crude analysis, loss to follow-up was highest
in West Africa and lowest in Central Africa and recorded mor-
tality was below 10% at 5 years across all regions.
In sensitivity analyses adjustment was based on the lower
and upper limits of the 95% CIs of the adjustment parameters
from the tracing studies [11]. Table 2 compares estimates at
years 1 to 5 for retention on ART, stopping ART, and mortal-
ity from sensitivity analyses with estimates from crude and
adjusted analyses. For example, the proportion of people who
stopped ART at 5 years was 30.6% based on the lower limit
and 1.8% based on the upper limit of the 95% CIs of the
adjustment parameters.
We analysed data from over 500,000 HIV-infected children
and adults who initiated ART in 22 countries in sub-Saharan
Africa. We adjusted for unrecorded deaths and silent transfers
among persons lost to follow-up and found that retention on
ART was considerably higher in the adjusted analysis. We
found that an estimated 19% of people who initiated ART had
stopped ART by 5 years. Cumulative mortality was 15% at
5 years, substantially higher in the adjusted analysis than the
analysis based on recorded deaths. The sensitivity analyses
showed that estimates for ART outcomes were sensitive to
the choice of adjustment parameters.
Our study has important implications for monitoring out-
comes of the scale-up of ART in sub-Saharan Africa in general,
and particularly monitoring progress towards the 90-90-90 tar-
gets. The second of the 90-90-90 targets states that at least
90% of people diagnosed with HIV should be receiving ART.
Our study could not assess this target directly because no data
on the number of people diagnosed with HIV during the study
period were available. However, both patients stopping and
patients not starting ARTwill compromise the second 90 target.
Our study shows that after several years of ART close to 20%
of all patients starting ART have stopped treatment. If WHO
guidelines for universal immediate ART are successfully imple-
mented [3], retention on ART will be one of the key determi-
nants of whether or not the second 90 target is met. Of note, a
recent review of national HIV care continua found that only one
country in sub-Saharan Africa, Swaziland, met the second of the
three 90 targets, and two other countries, Rwanda, and Namib-
ia, were close to achieving the target [19].
Our analysis has several limitations. We implemented WHO’s
definition of loss to follow-up and only consider the last recorded
status of patients at closure of database. Patients with transient
treatment interruptions who returned to care were considered
as retained throughout follow-up. Therefore, our analysis does
not take into account transient treatment interruptions and
retention estimates reflect the final status of patients at database
closure [20]. Our analysis therefore may overestimate retention.
Transient treatment interruption could be taken into account as
intermediate states in multistate models, but heterogeneity of
data makes it difficult to implement such analysis in multi-cohort
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studies [21,22]. Overall, 40% of people living with HIV were clas-
sified as lost to follow-up in the clinical databases of the ART pro-
grammes. These patients may have discontinued ART, self-
transferred to another programme, or died but their true out-
comes are unknown. Unrecorded deaths can be ascertained and
mortality estimates corrected by tracing patients lost to follow-
up or by linking the clinical databases to the vital registry [23,24].
We used inverse probability weighting to adjust for undocu-
mented mortality and self-transfers, based on the best available
data from a meta-analysis of tracing or linkage studies performed
in sub-Saharan Africa [11]. We assumed that the pooled esti-
mates from the meta-analysis were applicable to the IeDEA data
in all regions. The meta-analysis included tracing studies from
several countries in the East and Southern African IeDEA
regions, but only a few tracing studies from the West and Central
African IeDEA regions were available. We are thus more confi-
dent about the generalizability of the adjustment parameters to
East and Southern African IeDEA data, than for the West and
Central Africa regions. The goal of our study was to describe the
likely underestimate of mortality and retention in care at the
regional level. Our adjustment did not account for facility- or indi-
vidual-level characteristics, although ART outcomes may vary by
setting, clinic, and according to individual-level characteristics
such as CD4 cell count, age, gender, or pregnancy [4,7,15,25–
27]. Future studies should try to account for these factors. We
have begun tracing random samples of all patients lost to follow-
up using a standardized protocol in IeDEA Southern Africa to
generate adjustment factors for specific clinics in IeDEA. How-
ever, the pooled estimates from the meta-analysis are currently
the best available data to adjust our estimates. A further limita-
tion of our analysis is that the confidence intervals of the
adjusted estimates did not account for the statistical uncertainty
around adjustment parameters. However, we showed how uncer-
tainty around these parameters affected estimates for ART out-
comes in sensitivity analyses. Our study included some rural
primary care clinics, but larger urban secondary or tertiary care
hospitals dominated and our data are unlikely to be representa-
tive of all ART programmes in the countries involved [17]. A fur-
ther limitation of our adjustment parameters is that data on self-
transfer from tracing studies is usually self-reported and not
Table 1. Characteristics of patients at the start of antiretroviral therapy by IeDEA region
IeDEA region
Central Africa
12,848 (2.5%)
East Africa
109,233 (21.6%)
Southern Africa
347,343 (68.7%)
West Africa
36,210 (7.2%)
Total
505,634 (100.0%)
Age
<5 515 (4.0%) 8824 (8.1%) 12,317 (3.5%) 1283 (3.5%) 22,939 (4.5%)
5 to 14 866 (6.7%) 5145 (4.7%) 13,733 (4.0%) 1371 (3.8%) 21,115 (4.2%)
15+ 11,467 (89.3%) 95,264 (87.2%) 321,293 (92.5%) 33,556 (92.7%) 461,580 (91.3%)
Median (IQR) 33.1 (25.8 to 41.2) 32.8 (25.2 to 41.0) 33.8 (27.5 to 40.7) 35.7 (29.0 to 43.6) 33.7 (27.1 to 41.0)
Sex
Male 4504 (35.1%) 37,929 (34.7%) 132,159 (38.0%) 12,551 (34.7%) 187,143 (37.0%)
Female 8344 (64.9%) 71,304 (65.3%) 215,184 (62.0%) 23,659 (65.3%) 318,491 (63.0%)
Year of ART initiation
2009 to 2010 5012 (39.0%) 38,160 (34.9%) 107,392 (30.9%) 16,044 (44.3%) 166,608 (33.0%)
2011 to 2012 4521 (35.2%) 43,779 (40.1%) 114,656 (33.0%) 12,239 (33.8%) 175,195 (34.6%)
2013 to 2014 3315 (25.8%) 27,294 (25.0%) 125,295 (36.1%) 7927 (21.9%) 163,831 (32.4%)
CD4 cell count (cells/lL)
<200 2632 (30.6%) 34,101 (51.5%) 109,256 (50.2%) 11,710 (50.7%) 157,699 (50.0%)
200 to 349 4073 (47.4%) 19,882 (30.1%) 72,845 (33.5%) 6288 (27.2%) 103,088 (32.7%)
350 to 500 999 (11.6%) 5675 (8.6%) 18,837 (8.7%) 2293 (9.9%) 27,804 (8.8%)
>500 892 (10.4%) 6495 (9.8%) 16,809 (7.7%) 2797 (12.1%) 26,993 (8.6%)
Median (IQR) 276 (172 to 343) 194 (87 to 312) 199 (106 to 307) 196 (83 to 329) 200 (102 to 311)
Missing 4252 (33.1%) 43,080 (39.4%) 12,9596 (37.3%) 131,22 (36.2%) 190,050 (37.6%)
WHO clinical stage
I 2752 (36.1%) 28,484 (32.2%) 101,338 (37.8%) 6084 (33.5%) 138,658 (36.3%)
II 1776 (23.3%) 27,074 (30.6%) 56,979 (21.3%) 3557 (19.6%) 89,386 (23.4%)
III 2579 (33.8%) 25,622 (29.0%) 95,842 (35.8%) 6675 (36.7%) 130,718 (34.2%)
IV 519 (6.8%) 7249 (8.2%) 13,914 (5.2%) 1865 (10.3%) 23,547 (6.2%)
Missing 5222 (40.6%) 20,804 (19.0%) 79,270 (22.8%) 18,029 (49.8%) 123,325 (24.4%)
Data are number (%) of patients if not otherwise stated. ART, antiretroviral therapy; IeDEA, International epidemiology Databases to Evaluate
AIDS. WHO, World Health Organization. CD4 cell counts and WHO clinical stage were assessed at ART initiation.
Data are stratified by IeDEA region. Central Africa: Burundi, Dem. Rep. of Congo and Rwanda; East Africa: Kenya, Tanzania, Uganda; Southern
Africa: Lesotho, Malawi, Mozambique, South Africa, Zambia and Zimbabwe; West Africa: Benin, Burkina Faso, Co^te d’Ivoire, Ghana, Guinea, Gui-
nea-Bissau, Mali, Nigeria, Senegal and Togo.
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verified by clinical records. Over-reporting of self-transfer may
lead to overestimation of retention in care.
4 | CONCLUSION
Efforts to retain people living with HIV in long-term care and
to bring patients back to care must be intensified, both to
improve outcomes in individuals and to prevent HIV transmis-
sions at the population level [5]. Monitoring of progress must
take unrecorded mortality and silent transfers between clinics
into account.
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